The goal of Core C is high-throughput production and analysis of AML genome sequence data. This includes data production, somatic and germline variant detection and validation, integration of various data types, and statistical inference of genetic alterations and their clinical implications. This will be achieved by employing cutting-edge technologies to generate high-quality DNA and RNA sequencing data and by using computational methods and tools to accurately analyze, identify, and categorize disease-causing and/or clinically relevant sequence variants and expression/methylation changes. The genomic data produced in Core C for cfe novo AML samples, AML relapse samples, MDS/AML families, and treatment-related AMLs will be comprehensive, including whole genome, exome, capture validation, and mRNA/sncRNA. Data from existing publically available catalogues of cancer-specific mutations, inherited variants related to genetic disease, and expression/methylation signatures will be used to further inform our analysis and clinical interpretation of identified genetic alterations in AML. Moreover, we will integrate genomic, epigenomic, and expression data from all projects at the pathway and network levels to understand how a diverse spectrum of genetic changes works together to drive AML initiation and progression. Finally, we will integrate genotypic and phenotypic data to facilitate the classification and discovery of genomic variants with clinical relevance and prognostic significance.

Public Health Relevance

Core C will continue to produce and analyze high quality AML sequence data. This is critical for the success of this Program Project and, ultimately, for the better understanding of the genetic/genomic basis of AML.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Al-Hussaini, Muneera; Rettig, Michael P; Ritchey, Julie K et al. (2016) Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood 127:122-31
Welch, John S; Petti, Allegra A; Miller, Christopher A et al. (2016) TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375:2023-2036
Wong, Terrence N; Miller, Christopher A; Klco, Jeffery M et al. (2016) Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 127:893-7
Griffith, Malachi; Griffith, Obi L; Krysiak, Kilannin et al. (2016) Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol 44:603-13
Cole, Christopher B; Verdoni, Angela M; Ketkar, Shamika et al. (2016) PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest 126:85-98
Churpek, Jane E; Pyrtel, Khateriaa; Kanchi, Krishna-Latha et al. (2015) Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126:2484-90
Wong, Terrence N; Ramsingh, Giridharan; Young, Andrew L et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552-5
Engle, E K; Fisher, D A C; Miller, C A et al. (2015) Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29:869-76
Griffith, Malachi; Miller, Christopher A; Griffith, Obi L et al. (2015) Optimizing cancer genome sequencing and analysis. Cell Syst 1:210-223
Lu, Charles; Xie, Mingchao; Wendl, Michael C et al. (2015) Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun 6:10086

Showing the most recent 10 out of 98 publications